Ligand Pharmaceuticals Acquires XOMA Royalty for $739 Million

By Bobby Samwell • Tuesday, July 14 13:04 • Permanent Link

Ligand Pharmaceuticals completed its acquisition of XOMA Royalty for $39.00 a share in cash, valuing the deal at about $739 million.

The transaction adds seven commercial products to Ligand’s portfolio, including Vabysmo, Ojemda and Miplyffa, along with 14 late-stage development programs and more than 100 additional assets in various stages of development. Ligand said the deal more than doubles its royalty portfolio, taking it to more than 200 commercial, clinical and preclinical assets.

Ligand said the acquisition is expected to add about $0.50 per share to projected 2026 adjusted earnings and about $1.50 per share to projected 2027 adjusted earnings. The company said the closing came on its original timetable and that it will provide an updated five-year outlook at its investor day on Dec. 8, 2026.

XOMA Royalty stock stopped trading on Nasdaq after the deal closed. The market has reacted to these announcements by moving the company's shares -2.33% to a price of $302.03. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.